Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 7/20 | 0.49 |
| ▸ | OPRL1 | P41146 | 7/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.37 |
| ▸ | LTA4H | P09960 | 2/20 | 0.37 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 2/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14260462 | 0.82 | OPRM1 (0.49) | OPRM1OPRL1OPRD1OPRK1KCNA3 | |
| SCHEMBL5876108 | 0.75 | POLB (0.43) | OPRM1OPRL1MAOBMAOA | |
| SCHEMBL5848845 | 0.70 | OPRM1 (0.44) | OPRM1OPRL1OPRD1OPRK1CA4 | |
| SCHEMBL12893233 | 0.69 | OPRM1 (0.46) | OPRM1OPRL1OPRD1OPRK1CA4 | |
| SCHEMBL14531844 | 0.67 | PDE4B (0.48) | MAOA | |
| SCHEMBL14260464 | 0.67 | PDE4B (0.48) | MAOA | |
| SCHEMBL1257256 | 0.66 | OPRM1 (0.59) | OPRM1OPRL1OPRD1OPRK1CA4 | |
| SCHEMBL3407329 | 0.66 | OPRM1 (1.00) | OPRM1OPRL1OPRK1 | |
| SCHEMBL12893199 | 0.66 | OPRM1 (0.50) | OPRM1OPRL1KCNA3BACE1BACE2 | |
| SCHEMBL744007 | 0.65 | MEN1 (0.44) | OPRM1OPRL1OPRK1MAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8822548-B2 | Compounds with activity at estrogen receptors | ACADIA PHARMACEUTICALS INC. (US) | 2014-09-02 | — | — | US | disclosed |
| US-20110046237-A1 | COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTORS | ACADIA PHARMACEUTICALS INC. (US) | 2011-02-24 | — | — | US | disclosed |
| US-7825265-B2 | di-aromatic compounds for treatment and prevention of diseases and disorders related to estrogen receptors; 2-fluoro-1-methoxy-4-(1-phenyl-cyclohexyl)-benzene | ACADIA PHARMACEUTICALS INC. (US) | 2010-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046237-A1 | COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTORS | ESR2, ESR1, GPER1 | OPRM1 341/4885OPRL1 186/4885OPRD1 353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.